United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the company’s stock in a transaction that occurred on Wednesday, June 17th. The stock was sold at an average price of $552.40, for a total value of $5,247,800.00. Following the transaction, the chief executive officer directly owned 40,513 shares of the company’s stock, valued at approximately $22,379,381.20. This trade represents a 19.00% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

United Therapeutics Stock Down 2.7%

Shares of UTHR stock opened at $536.59 on Friday. The company’s fifty day simple moving average is $565.37 and its 200-day simple moving average is $523.32. The firm has a market cap of $22.78 billion, a PE ratio of 19.81, a P/E/G ratio of 1.80 and a beta of 0.57. United Therapeutics Corporation has a 12 month low of $272.12 and a 12 month high of $609.35.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing the consensus estimate of $7.00 by ($1.18). United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The business had revenue of $781.50 million for the quarter, compared to analyst estimates of $797.40 million. During the same quarter in the previous year, the company posted $6.63 EPS. The business’s revenue for the quarter was down 1.6% compared to the same quarter last year. On average, equities analysts predict that United Therapeutics Corporation will post 26.84 earnings per share for the current fiscal year.

Hedge Funds Weigh In On United Therapeutics

Hedge funds have recently bought and sold shares of the company. Avoro Capital Advisors LLC boosted its position in United Therapeutics by 17.3% during the fourth quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock valued at $1,269,803,000 after acquiring an additional 383,838 shares during the last quarter. Wellington Management Group LLP raised its position in shares of United Therapeutics by 74.5% in the 4th quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock worth $1,189,617,000 after acquiring an additional 1,042,711 shares in the last quarter. AQR Capital Management LLC lifted its stake in shares of United Therapeutics by 29.9% in the 4th quarter. AQR Capital Management LLC now owns 1,281,699 shares of the biotechnology company’s stock valued at $624,508,000 after purchasing an additional 295,221 shares during the period. Janus Henderson Group PLC lifted its stake in shares of United Therapeutics by 8.9% in the 1st quarter. Janus Henderson Group PLC now owns 866,930 shares of the biotechnology company’s stock valued at $514,016,000 after purchasing an additional 70,829 shares during the period. Finally, Darwin Global Management Ltd. bought a new stake in shares of United Therapeutics during the 3rd quarter valued at about $317,617,000. Institutional investors own 94.08% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the company. Oppenheimer raised their price objective on United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a report on Thursday, February 26th. Bank of America raised their price target on shares of United Therapeutics from $569.00 to $626.00 and gave the stock a “neutral” rating in a research report on Tuesday, March 31st. TD Cowen reaffirmed a “buy” rating on shares of United Therapeutics in a report on Thursday, May 21st. Jefferies Financial Group restated a “buy” rating on shares of United Therapeutics in a research report on Monday, March 2nd. Finally, Weiss Ratings reaffirmed a “buy (b)” rating on shares of United Therapeutics in a report on Thursday, June 11th. Eleven research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $619.42.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.